• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 HLA mismatched 异基因干细胞移植后,通过输注来自多个供体的第三方 T 细胞,联合抗病毒药物、利妥昔单抗和手术,成功治疗了 CMV、EBV 和腺病毒组织感染。

Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA-mismatched allogeneic stem cell transplant using infusion of third-party T cells from multiple donors in addition to antivirals, rituximab, and surgery.

机构信息

Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.

Stem Cell Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, Australia.

出版信息

Transpl Infect Dis. 2021 Apr;23(2):e13528. doi: 10.1111/tid.13528. Epub 2020 Dec 6.

DOI:10.1111/tid.13528
PMID:33236399
Abstract

Viral infections, principally cytomegalovirus, Epstein Barr virus (EBV) and adenovirus, are a leading cause of morbidity and mortality after allogeneic stem cell transplantation. The use of systemic antivirals is limited by limited efficacy and organ toxicities. Inability to clear infection is exacerbated by transplant-related immunosuppression and prophylaxis or treatment of acute graft versus host disease. We report the first patient to clear three serious viral infections after stem cell transplant using third-party donor partially human leukocyte antigen (HLA) matched virus-specific cytotoxic T cells. The patient, a 53 year old female with transplanted for relapsed leukemia, with severe graft versus host disease received five T cell infusions from three separate donors that ultimately cleared serious systemic infections with cytomegalovirus and adenovirus, and an EBV-driven lymphoma. Systemic antivirals had resulted in failed clinical responses. Use of repeated infusions of partially HLA matched virus-specific T cells from banks containing cryopreserved cells should be strongly considered in transplant recipients with single or multiple refractory viral infections.

摘要

病毒感染,主要是巨细胞病毒、Epstein Barr 病毒(EBV)和腺病毒,是异基因干细胞移植后发病率和死亡率的主要原因。由于疗效有限和器官毒性,全身抗病毒药物的使用受到限制。移植相关免疫抑制以及急性移植物抗宿主病的预防或治疗加剧了无法清除感染的情况。我们报告了首例使用第三方供体部分人白细胞抗原(HLA)匹配的病毒特异性细胞毒性 T 细胞清除干细胞移植后三种严重病毒感染的患者。该患者为 53 岁女性,因复发白血病接受移植,伴有严重移植物抗宿主病,从三名供体接受了五次 T 细胞输注,最终清除了严重的全身巨细胞病毒和腺病毒感染以及 EBV 驱动的淋巴瘤。系统性抗病毒药物治疗导致临床反应失败。对于患有单一或多种难治性病毒感染的移植受者,应强烈考虑使用来自含有冷冻细胞的银行的重复输注部分 HLA 匹配的病毒特异性 T 细胞。

相似文献

1
Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA-mismatched allogeneic stem cell transplant using infusion of third-party T cells from multiple donors in addition to antivirals, rituximab, and surgery.在 HLA mismatched 异基因干细胞移植后,通过输注来自多个供体的第三方 T 细胞,联合抗病毒药物、利妥昔单抗和手术,成功治疗了 CMV、EBV 和腺病毒组织感染。
Transpl Infect Dis. 2021 Apr;23(2):e13528. doi: 10.1111/tid.13528. Epub 2020 Dec 6.
2
CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.CMV、EBV 和 ADV 特异性 T 细胞免疫:筛选和监测潜在的第三方供体,以改善移植后的结果。
Biol Blood Marrow Transplant. 2013 Oct;19(10):1480-92. doi: 10.1016/j.bbmt.2013.07.015. Epub 2013 Jul 23.
3
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.生产符合良好生产规范的、针对 Epstein-Barr 病毒、巨细胞病毒和腺病毒的细胞毒性 T 淋巴细胞,以预防或治疗异基因造血干细胞移植后病毒感染。
Cytotherapy. 2012 Jan;14(1):7-11. doi: 10.3109/14653249.2011.636963.
4
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.异基因干细胞移植后首次病毒再激活的第三方 CMV 和 EBV 特异性 T 细胞。
Blood Adv. 2022 Sep 13;6(17):4949-4966. doi: 10.1182/bloodadvances.2022007103.
5
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.同种异体造血干细胞移植后,三病毒靶向 T 细胞快速生成治疗腺病毒、EBV 和 CMV 感染的安全性和临床疗效。
Mol Ther. 2013 Nov;21(11):2113-21. doi: 10.1038/mt.2013.151. Epub 2013 Jun 20.
6
Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.评估适合的靶抗原和免疫测定法,用于对巨细胞病毒和EB病毒特异性T细胞进行高精度免疫监测,这些细胞是免疫治疗方法中感兴趣的靶标。
J Immunol Methods. 2014 Jun;408:101-13. doi: 10.1016/j.jim.2014.05.011. Epub 2014 May 28.
7
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.现成的EBV特异性T细胞免疫疗法用于移植后利妥昔单抗难治性EBV相关淋巴瘤。
J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127.
8
Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation.同种异体干细胞移植后治疗 CMV 感染中,移植供体和第三方 CMV 特异性 T 细胞具有可比的抗 CMV 反应。
Cell Mol Immunol. 2022 Apr;19(4):482-491. doi: 10.1038/s41423-021-00829-y. Epub 2022 Jan 11.
9
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.第三方及患者特异性供体来源的病毒特异性T细胞在儿童和青年造血干细胞移植后病毒感染管理中显示出相似的疗效和安全性。
Transplant Cell Ther. 2023 May;29(5):305-310. doi: 10.1016/j.jtct.2023.01.027. Epub 2023 Feb 3.
10
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.供体T细胞的细胞毒性T淋巴细胞疗法可预防和治疗单倍体相合及匹配无关供者干细胞移植后的腺病毒和EB病毒感染。
Blood. 2009 Nov 5;114(19):4283-92. doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21.

引用本文的文献

1
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years.15年来,通过同情用药获得病毒特异性T细胞进行过继性免疫治疗。
Nat Commun. 2024 Dec 3;15(1):10339. doi: 10.1038/s41467-024-54595-2.
2
Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.新兴的抗人类腺病毒感染治疗药物:最新进展和新策略。
Antiviral Res. 2021 Apr;188:105034. doi: 10.1016/j.antiviral.2021.105034. Epub 2021 Feb 10.